611 Gateway Blvd
South San Francisco
About Alumis Inc.
Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Our experienced leadership team brings a proven track record in precision drug development of groundbreaking therapies.
Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer.
With a unique precision analytics platform and an unwavering commitment to advancing our understanding of immunologic diseases, Alumis Inc. will rewrite the autoimmune treatment playbook by developing the right medicine for each patient.
6 articles with Alumis Inc.
Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer
Alumis today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.
Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.
Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases
Alumis, formerly Esker Therapeutics, today announced the completion of a $200 million financing led by AyurMaya, an affiliate of Matrix Capital Management, and by a U.S.-based healthcare-focused fund.
Esker Therapeutics Announces Management and Research Team Additions to Accelerate Advancement of Precision Immunology Therapies
Esker Therapeutics today announced that Martin Babler has joined the company as president, chief executive officer and chairman of the board of directors.
Esker Therapeutics today announced the appointment of Jeff Douglas as vice president of clinical operations.
Esker Therapeutics today announced the appointment of several new team members: Kimberly Lindstorm, Ph.D., as vice president, regulatory. Travis Remarchuk, Ph.D., as executive director, CMC. Zhengbin (Bing) Yao, Ph.D., as a member of the board of directors.